MarcAndrewRiedlMD
Allergy & Immunology • San Diego, CAProfessor of Medicine, University of California - San Diego
Dr. Riedl is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8899 University Center Lane
#230
San Diego, CA 92122Phone+1 858-657-5350
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Allergy and Immunology, 2001 - 2003
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1998 - 2001
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1998
Certifications & Licensure
CA State Medical License 2001 - 2027- American Board of Allergy and Immunology Allergy & Immunology
Clinical Trials
- Diesel Exhaust Particles and Leukotriene Production Start of enrollment: 2008 Apr 01
- Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema Start of enrollment: 2013 Dec 02
- A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants Start of enrollment: 2014 May 14
Publications & Presentations
PubMed
- Clinical burden, treatment, and disease control in patients with chronic spontaneous urticaria: Real-world evidence.Marc A Riedl, Dhaval Patil, Jonathan Rodrigues, Merin Kuruvilla, Tara Raftery
Annals of Allergy, Asthma & Immunology. 2024-12-16 - Development and validation of a US quality of life instrument for hereditary angioedema due to C1 inhibitor deficiency.Anthony J Castaldo, Nikolaj Siersbæk, Deborah Corcoran, Christine N Selva, Christian Jervelund
Annals of Allergy, Asthma & Immunology. 2024-12-01 - 2 citationsThe future of therapeutic options for hereditary angioedema.Tukisa D Smith, Marc A Riedl
Annals of Allergy, Asthma & Immunology. 2024-10-01
Journal Articles
- Effect of Lanadelumab Compared with Placebo on Prevention of Hereditary Angioedema AttacksJonathan A Bernstein, Lawrence B Schwartz, Andrew M Smith, H James Wedner, Daniel Soteres, Timothy Craig, Douglas T Johnston, Aleena Banerji, Paula J Busse, William R ..., JAMA
- Population Pharmacokinetics of Subcutaneous C1‐Inhibitor for Prevention of Attacks in Patients with Hereditary AngioedemaJonathan A Bernstein, Marc A Riedl, Bruce Zuraw, H Henry Li, Timothy Craig, William R Lumry, Clinical and experimental allergy
- Update on the Use of C1-Esterase Inhibitor Replacement Therapy in the Acute and Prophylactic Treatment of Hereditary AngioedemaMarc Riedl, Jay Kashkin, Clinical Reviews in Allergy & Immunology
Press Mentions
BioCryst Presents New Data Showing Sustained Reduction of HAE Attack Rates and Improved Patient Satisfaction After Patients Switch to ORLADEYO® (Berotralstat)November 5th, 2021
New Analyses from the Phase 3 HELP Study™ Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO® (Lanadelumab-Flyo) Injection During Extended Study Treatment PeriodNovember 8th, 2019
New Data from Pivotal Phase 3 Study Investigating Lanadelumab as a Prophylactic Treatment for HAE to Be Presented at 2018 AAAAI/WAO Joint CongressMarch 3rd, 2018- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
